Your browser doesn't support javascript.
loading
Phase III Non-inferiority Study Evaluating Efficacy and Safety of Low Dose Gemcitabine Compared to Standard Dose Gemcitabine With Platinum in Advanced Squamous Lung Cancer.
Patil, Vijay; Noronha, Vanita; Joshi, Amit; Chougule, Anuradha; Kannan, Sadhana; Bhattacharjee, Atanu; Goud, Supriya; More, Sucheta; Chandrasekharan, Arun; Menon, Nandini; Srinivas, Sujay; Vallathol, Dilip Harindran; Dsouza, Hollis; Majumdar, Swaratika; Das, Sudeep; Zawar, Abhinav; Khaddar, Satvik; Kumar, Amit; Singh, Gunjesh; Kumar, Kanteti Aditya Pavan; Ravind, Rahul; Trivedi, Vaishakhi; Behel, Vichitra; Mahajan, Abhishek; Janu, Amit; Purandare, Nilendu; Prabhash, Kumar.
Afiliação
  • Patil V; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Noronha V; Homi Bhabha National Institute, Mumbai, India.
  • Joshi A; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Chougule A; Homi Bhabha National Institute, Mumbai, India.
  • Kannan S; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Bhattacharjee A; Homi Bhabha National Institute, Mumbai, India.
  • Goud S; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • More S; Homi Bhabha National Institute, Mumbai, India.
  • Chandrasekharan A; Department of Cancer Epidemiology and Biostatistics, Tata Memorial Hospital, Mumbai, India.
  • Menon N; Homi Bhabha National Institute, Mumbai, India.
  • Srinivas S; Department of Cancer Epidemiology and Biostatistics, Tata Memorial Hospital, Mumbai, India.
  • Vallathol DH; Homi Bhabha National Institute, Mumbai, India.
  • Dsouza H; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Majumdar S; Homi Bhabha National Institute, Mumbai, India.
  • Das S; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Zawar A; Homi Bhabha National Institute, Mumbai, India.
  • Khaddar S; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Kumar A; Homi Bhabha National Institute, Mumbai, India.
  • Singh G; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Kumar KAP; Homi Bhabha National Institute, Mumbai, India.
  • Ravind R; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Trivedi V; Homi Bhabha National Institute, Mumbai, India.
  • Behel V; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Mahajan A; Homi Bhabha National Institute, Mumbai, India.
  • Janu A; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
  • Purandare N; Homi Bhabha National Institute, Mumbai, India.
  • Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, India.
EClinicalMedicine ; 9: 19-25, 2019 Mar.
Article em En | MEDLINE | ID: mdl-31143878
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: EClinicalMedicine Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Índia
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Clinical_trials Idioma: En Revista: EClinicalMedicine Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Índia